Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lyra Therapeutics

Request full access

Lyra Therapeutics is a clinical-stage company developing medicines

Watertown, United StatesFounded 2018Biotech & Life Sciences

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. The company leverages its expertise in materials science, drug development, and formulation to create proprietary technology designed to deliver medicines directly, precisely, and consistently to the affected tissue for sustained periods with a single administration. Lyra Therapeutics' product candidates, LYR-210 and LYR-220, are bioabsorbable nasal implants intended to deliver up to six months of continuous mometasone furoate drug therapy through a brief, in-office procedure. The company's business model revolves around the development and commercialization of these specialized treatments, targeting patients suffering from CRS who cycle through various treatment options seeking lasting relief. Lyra Therapeutics operates in the biotechnology and pharmaceutical markets, primarily serving healthcare providers and patients dealing with CRS. The company generates revenue through the development, approval, and eventual sale of its proprietary drug delivery systems.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2018
Headquarters
Watertown, United States
Listing
IPO 2020
Sector
Biotech & Life Sciences

Lyra Therapeutics in the Watertown ecosystem

Live from Dealroom

The Lyra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Series B and later7 investors entered at this stage

  • Clinton Capital Partners
  • Nantahala Capital Management
  • Venrock Healthcare Capital Partners
  • North Bridge Venture Partners
  • Citadel
  • Samsara BioCapital
  • Woodline Partners
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lyra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lyra Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.